Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE)
  • The company has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe
  • DGWA will engage prospective investors and drive awareness of Recce's products
  • Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union
  • The company will keep the market updated as the listing progresses
  • Shares in Recce are steady on the market and are trading at $1.05 per share

Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE).

The FSE is the tenth-largest stock exchange in the world, third-largest in Europe and is owned and operated by Deutsche Börse AG and Börse Frankfurt Zertifikate AG.

Recce has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe.

DGWA will engage prospective investors and drive awareness of Recce's products.

"We are excited to support Recce in engagement with European investors and opportunities to expand its infectious disease programs," DGWA CEO Stefan Müller said.

Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union.

"Dual listing on the FSE enables Recce to broaden its exposure to European investors," Chairman Dr John Prendergast said.

"The company considers that it meets the requirement necessary to dual list on the FSE and will provide updates on its application process," he added.

Recce expects further developments regarding the listing process will be completed in the upcoming weeks.

Shares in Recce are steady on the market and are trading at $1.05 each.

RCE by the numbers
More From The Market Herald
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong (centre-left) - The Market Herald

" Imugene (ASX:IMU) increases loss, ramps up trials and research

Imugene (IMU) has ended the half-year with a $6 million loss after increasing its spending on clinical trials and research.
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) pockets $830K R&D rebate

Medical technology player LBT Innovations (LBT) has pocketed $830,000 under a government research and development tax incentive.
Palla Pharma (ASX:PAL) - Departing CEO, Jarrod Ritchie - The Market Herald

" Palla Pharma (ASX:PAL) to raise $18M to reduce debt

Palla Pharma (PAL) has announced plans to tap investors and shareholders for an extra $18 million in capital via a fundraise.
- Incoming Non Executive Director & Audit Committee Chair, Luisa Ingargiola - The Market Herald

" MyFiziq (ASX:MYQ) gears up for NASDAQ listing with substantiative new board appointments

MyFiziq (MYQ) has appointed two new board members as it gears up to launch on the NASDAQ.